Prof. Dr. Christoph Correll

Medical Director, RAP Program, The Zucker Hillside Hospital, Professor of Psychiatry, Hofstra Northwell School of Medicine, New York, USA

Prof. Dr. Christoph Correll

Medical Director, RAP Program, The Zucker Hillside Hospital, Professor of Psychiatry, Hofstra Northwell School of Medicine, New York, USA

Biography

Christoph Correll, MD, is currently Professor of Psychiatry at Hofstra Northwell School of Medicine, New York, USA and Medical Director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital, New York, USA. He completed his medical studies at both the Free University of Berlin in Germany, and at the Dundee University Medical School in Scotland. He is board certified in both general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City.

Professor Correll’s research and clinical work focus on the identification, characterisation and treatment of adults and youths with severe psychiatric disorders. His areas of expertise include the prodrome, first episode, multi-episode and refractory illness phase of severe psychotic and mood disorders, including schizophrenia, bipolar disorder, major depression, as well as aggressive spectrum disorders. He further focuses on psychopharmacology and comparative effectiveness, the risk–benefit evaluation of psychotropic medications, as well as the extent and mechanisms of cardiometabolic and neuromotor adverse effects.

Professor Correll has authored or co-authored over 350 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Professor Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received over 30 national and international research awards and fellowships for his work and was listed by Thomson Reuters in 2014 and 2015 as one of “The most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.